UNSPSC 51342704: Boceprevir

This classification denotes a protease inhibitor and antiviral with the molecular formula C27H45N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 89BT58KELH, chemically known as (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[(2S)-2-(tert-butylcarbamoylamino)-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide but generally known as Boceprevir, which bears US NIH Compound Identifier 10324367. Boceprevir most often comes in base and sulfate forms.

UNSPSC 51342704 Boceprevir, a Commodity code, does not reflect meaningful recent state and local procurement activity aligned with its nominal scope. The two most recent opportunities flagged under this code involve unrelated pharmaceutical products: the Illinois Department of Public Health awarded a completed piggyback contract through MMCAP Infuse to Chartwell Rx LLC for Doxycycline Hyclate and Ciprofloxacin Hydrochloride (neither antiviral hepatitis C treatments), and Seminole County, Florida issued an IFB for Naloxone and safe drug deactivation systems. The coding mismatch indicates that state and local procurement systems are tagging these opportunities with a boceprevir commodity code despite the absence of boceprevir procurement in either record.

State and local procurement bodies do not appear to be actively sourcing boceprevir through open solicitations at this time. Issuers across the state and local tier use piggyback cooperative purchasing vehicles and traditional IFBs for pharmaceutical supply, but the recent record shows no open demand for this specific antiviral. Business development professionals should treat this code as dormant for near-term capture; activity, if it emerges, would likely flow through state health department or hospital system cooperative purchasing frameworks rather than direct agency IFBs.